Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

The Lancet Psychiatry

Volumn 3, Issue 7, 2016, Pages 619-627

  Carhart Harris, Robin L ^a   Bolstridge, Mark ^a   Rucker, James ^a,c   Day, Camilla M J ^a   Erritzoe, David ^a   Kaelen, Mendel ^a   Bloomfield, Michael ^e   Rickard, James A ^f   Forbes, Ben ^d   Feilding, Amanda ^g   Taylor, David ^b   Pilling, Steve ^e   Curran, Valerie H ^e   Nutt, David J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f ROYAL LONDON HOSPITAL   (United Kingdom)

^g THE BECKLEY FOUNDATION   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PSILOCYBINE; SEROTONIN AGONIST;

ADULT; ANHEDONIA; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DEPRESSION ASSESSMENT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; LOW DRUG DOSE; MALE; MIDDLE AGED; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOTHERAPY; QUESTIONNAIRE; RISK ASSESSMENT; THOUGHT DISORDER; TREATMENT RESISTANT DEPRESSION; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEASIBILITY STUDY; PSYCHOLOGY; SOCIAL SUPPORT; TREATMENT OUTCOME;

ADULT; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PSILOCYBIN; SEROTONIN RECEPTOR AGONISTS; SOCIAL SUPPORT; TREATMENT OUTCOME;

EID: 84969243983     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(16)30065-7     Document Type: Article

References (29)

1. 1 Hofmann, A, Frey, A, Ott, H, Petr Zilka, T, Troxler, F, Elucidation of the structure and the synthesis of psilocybin. Experientia 14 (1958), 397–399.
2. 2 Hofmann, A, Heim, R, Brack, A, Kobel, H, Psilocybin, a psychotropic substance from the Mexican mushroom Psilicybe mexicana Heim. Experientia 14 (1958), 107–109.
3. 3 Halberstadt, AL, Geyer, MA, Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology 61 (2011), 364–381.
4. 2C receptor antagonists on serial spatial reversal learning in rats. Neuropsychopharmacology 33 (2008), 2007–2019.
5. (2A) receptor in learning. Learn Mem 10 (2003), 355–362.
6. 6 Vaidya, VA, Marek, GJ, Aghajanian, GK, Duman, RS, 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci 17:8 (1997), 2785–2795.
7. 2 signalling. J Psychopharmacol 28 (2014), 545–552.
8. 8 Griffiths, R, Richards, W, Johnson, M, McCann, U, Jesse, R, Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 22 (2008), 621–632.
9. 9 Carhart-Harris, RL, Kaelen, M, Bolstridge, M, et al. The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychol Med 46 (2016), 1379–1390.
10. 10 Carhart-Harris, RL, Erritzoe, D, Williams, T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci USA 109 (2012), 2138–2143.
11. 11 Hendricks, PS, Thorne, CB, Clark, CB, Coombs, DW, Johnson, MW, Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol 29 (2015), 280–288.
12. 12 Krebs, TS, Johansen, PO, Psychedelics and mental health: a population study. PLoS One, 8, 2013, e63972.
13. 13 Bouso, JC, Gonzalez, D, Fondevila, S, et al. Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal study. PLoS One, 7, 2012, e42421.
14. 14 Gasser, P, Holstein, D, Michel, Y, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202 (2014), 513–520.
15. 15 Grob, CS, Danforth, AL, Chopra, GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68 (2011), 71–78.
16. 16 Osorio Fde, L, Sanches, RF, Macedo, LR, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Rev Bras Psiquiatr 37 (2015), 13–20.
17. 17 Moreno, FA, Wiegand, CB, Taitano, EK, Delgado, PL, Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 67 (2006), 1735–1740.
18. 18 Johnson, MW, Garcia-Romeu, A, Cosimano, MP, Griffiths, RR, Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 28 (2014), 983–992.
19. 19 Bogenschutz, MP, Forcehimes, AA, Pommy, JA, Wilcox, CE, Barbosa, P, Strassman, RJ, Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 29 (2015), 289–299.
20. 20 Johnson, M, Richards, W, Griffiths, R, Human hallucinogen research: guidelines for safety. J Psychopharmacol 22 (2008), 603–620.
21. 21 Greenberg, PE, Fournier, AA, Sisitsky, T, Pike, CT, Kessler, RC, The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry 76 (2015), 155–162.
22. 22 Gaynes, BN, Identifying difficult-to-treat depression: differential diagnosis, subtypes, and comorbidities. J Clin Psychiatry 70:suppl 6 (2009), 10–15.
23. 23 Sackeim, HA, The definition and meaning of treatment-resistant depression. J Clin Psychiatry 62:suppl 16 (2001), 10–17.
24. 24 Studerus, E, Gamma, A, Vollenweider, FX, Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS One, 5, 2010, e12412.
25. 25 Rush, AJ, Trivedi, MH, Ibrahim, HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54 (2003), 573–583.
26. 26 Ibrahim, L, DiazGranados, N, Franco-Chaves, J, et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacol 37 (2012), 1526–1533.
27. 27 Johnson, MW, Sewell, RA, Griffiths, RR, Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Depend 123 (2012), 132–140.
28. 28 Carhart-Harris, RL, Kaelen, M, Whalley, MG, Bolstridge, M, Feilding, A, Nutt, DJ, LSD enhances suggestibility in healthy volunteers. Psychopharmacology 232 (2015), 785–794.
29. 29 Bonson, KR, Buckholtz, JW, Murphy, DL, Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 14 (1996), 425–436.